◆ Market Terminal AILook up a stock

Starling Oncology, Inc. (STLN)

Healthcare · Medical - Care Facilities · Small-cap · updated October 16, 2026

ON OUR BUY LIST
What this means. Starling Oncology, Inc. is an average business by our measures, its shares look cheap compared with other stocks, and its share price has been doing well.
Value79
Quality50
Price trend96
Overall74
13 of 2764rank among the US stocks we score (our core model buys the top 15)
100%of US stocks we score rank below it

Scores are 0 to 100 against every US stock we track; 50 is average. Recomputed after every US market close.

The business in numbers

Fiscal year to December 2025, from the company's annual filing with the SEC.

Salesyearly sales$502.7M
Sales growthchange from the year before+27.8%
Operating marginshare of sales left after running the business-7.2%
Net marginshare of sales kept as profit12055.4%
Free-cash-flow marginspare cash generated per $100 of sales-5.5%
Return on equityprofit vs. shareholders' accounting valuen/m
Debt / equitydebt vs. shareholders' accounting valuen/m
Change in share countnegative = the company is buying back its shares+23.1%

Insider trades, last 90 days

1 insider bought $95K on the open market.

Chernett Jorey10% ownerBoughtJul 2118,000 shat $5.27 · $95K

From Form 4 filings with the SEC. Open-market trades only. "Plan" = a sale set up in advance under a 10b5-1 plan, usually routine.

Interactive lookupGet the Ledger every Monday

Not financial advice. Research and education only: the same view for everyone, with no regard to your circumstances. Past results do not predict future ones. Decide for yourself or with a licensed adviser. Terms · Privacy